Trade Ligand Pharmaceuticals Incorpor - LGND CFD
Add to favourite- Summary
- Historical Data
| Spread | 1.25 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023457% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001235% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 106.69 |
| Open | 105.88 |
| 1-Year Change | 50.08% |
| Day's Range | 105.88 - 108.89 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 28, 2025 | 107.71 | 2.04 | 1.93% | 105.67 | 109.01 | 104.68 |
| Apr 25, 2025 | 106.69 | 0.80 | 0.76% | 105.89 | 108.05 | 103.33 |
| Apr 24, 2025 | 107.47 | 2.57 | 2.45% | 104.90 | 108.99 | 102.19 |
| Apr 23, 2025 | 104.79 | -1.53 | -1.44% | 106.32 | 110.20 | 104.78 |
| Apr 22, 2025 | 105.42 | 2.29 | 2.22% | 103.13 | 107.05 | 103.13 |
| Apr 21, 2025 | 103.82 | 0.90 | 0.87% | 102.92 | 105.30 | 101.79 |
| Apr 17, 2025 | 104.64 | 3.55 | 3.51% | 101.09 | 105.34 | 100.55 |
| Apr 16, 2025 | 102.69 | -1.48 | -1.42% | 104.17 | 105.90 | 101.62 |
| Apr 15, 2025 | 105.35 | 3.14 | 3.07% | 102.21 | 106.90 | 101.49 |
| Apr 14, 2025 | 105.60 | 2.20 | 2.13% | 103.40 | 107.33 | 100.03 |
| Apr 11, 2025 | 103.91 | 5.27 | 5.34% | 98.64 | 104.71 | 98.64 |
| Apr 10, 2025 | 101.11 | 0.54 | 0.54% | 100.57 | 103.24 | 96.38 |
| Apr 9, 2025 | 102.49 | 7.59 | 8.00% | 94.90 | 105.29 | 92.78 |
| Apr 8, 2025 | 95.35 | -3.98 | -4.01% | 99.33 | 102.15 | 94.03 |
| Apr 7, 2025 | 95.51 | 1.93 | 2.06% | 93.58 | 102.44 | 92.88 |
| Apr 4, 2025 | 99.39 | 1.80 | 1.84% | 97.59 | 100.89 | 96.11 |
| Apr 3, 2025 | 102.27 | -0.81 | -0.79% | 103.08 | 106.24 | 101.30 |
| Apr 2, 2025 | 108.29 | 6.22 | 6.09% | 102.07 | 108.49 | 101.62 |
| Apr 1, 2025 | 103.82 | 1.62 | 1.59% | 102.20 | 106.97 | 101.37 |
| Mar 31, 2025 | 104.79 | -0.11 | -0.10% | 104.90 | 104.99 | 101.57 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Ligand Pharmaceuticals Incorpor Company profile
About Ligand Pharmaceuticals Inc.
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company. The Company is focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. It has partnerships and license agreements with approximately 140 pharmaceutical and biotechnology companies and 400 programs are in various stages of commercialization, development or research and are fully funded by its collaboration partners and licensees. Its technologies include OmniAb Technologies, Pelican Expression Technology Platform, Captisol Technology, HepDirect, LTP, BEPro Technology Platform, and SUREtechnology Platform. The OmniAb platform creates and screens diverse antibody pools and is designed to identify optimal antibodies. The Pelican Expression Technology is a scalable platform for recombinant protein production and is suited for complex, large-scale protein production. Captisol is a chemically modified cyclodextrin designed to optimize the stability of drugs.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Ligand Pharmaceuticals Inc. revenues increased 49% to $277.1M. Net income totaled $57.1M vs. loss of $3M. Revenues reflect Captisol segment increase of 49% to $164.3M, Milestone segment increase from $11.5M to $28.7M. Net Income reflects Gain (loss) from short-term investments decrease of 76% to $4M (expense), Other General and administrative decrease of 23% to $36.1M (expense).
Equity composition
Common Stock $.006 Par, 3/11, 33,333,3333 auth., 20,644,234 issd., less 1,118,222 shs in Treas. @ $42.3M. Insiders own 3.36%. IPO:11/92, 4.3M Class A shares @ $11 by Lehman Bros. FY'00 Q's are restated for SAB 101 adjustment. 9/05,Co. delisted from NASDAQ to OTC.11/10, 1-for-06 Reverse Stock split.
| Industry: | Pharmaceuticals (NEC) |
3911 Sorrento Valley Blvd
Suite 110
SAN DIEGO
CALIFORNIA 92121
US
News
GME shares price forecast: Third-party price target
Read our GameStop (GME) share price forecast for 2025 and beyond, with insights from third-party analysts and market experts
11:40, 28 April 2025
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com